European Journal of Heart Failure

Article	Citations
Epidemiology of heart failure	907
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure	762
Myocardial localization of coronavirus in COVID‐19 cardiogenic shock	710
Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Soci	575
Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio‐O	352
Epidemiology, pathophysiology and contemporary management of cardiogenic shock – a position statement from the Heart Failure Association of the European Society of Cardiology	230
Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), th	216
Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial	188
How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardio	188
COVID‐19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease	187
Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio‐Oncology Study Group of the Heart Failure Association and	177
Self‐care of heart failure patients: practical management recommendations from the Heart Failure Association of the European Society of Cardiology	168
Heart failure in COVID‐19 patients: prevalence, incidence and prognostic implications	166
Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology	152
The impact of COVID‐19 on heart failure hospitalization and management: report from a Heart Failure Unit in London during the peak of the pandemic	149
Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial	146
Pulmonary artery pressure‐guided therapy in ambulatory patients with symptomatic heart failure: the CardioMEMS European Monitoring Study for Heart F	142
The Heart Failure Association Atlas: Heart Failure Epidemiology and Management Statistics 2019	119
Prevalence and prognostic impact of the coexistence of multiple frailty domains in elderly patients with heart failure: the FRAGILE‐HF cohort study	114
Angiotensin‐converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID‐19 infection in a multi‐site UK acute hospital trust	113
Quality of life in heart failure with preserved ejection fraction: importance of obesity, functional capacity, and physical inactivity	106
Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy	101
Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) and long‐term extension study	100
Circulating cardiovascular microRNAs in critically ill COVID‐19 patients	100
Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care	98

Depression and heart failure: the lonely comorbidity	98
Sodium–glucose co‐transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology	96
Impact of heart failure on the clinical course and outcomes of patients hospitalized for COVID‐19. Results of the Cardio‐COVID‐Italy multicentre study	94
Primary results of long‐term outcomes in the MOMENTUM 3 pivotal trial and continued access protocol study phase: a study of 2200 HeartMate 3 left ventricular assist device implan	93
Management of heart failure patients with COVID‐19: a joint position paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association	92
Characterization of the inflammatory‐metabolic phenotype of heart failure with a preserved ejection fraction: a hypothesis to explain influence of sex on the evolution and potential treatme	90
An expert consensus document on the management of cardiovascular manifestations of Fabry disease	88
Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR‐Preserved trial	86
Integration of a palliative approach into heart failure care: a European Society of Cardiology Heart Failure Association position paper	85
Rapid evidence‐based sequencing of foundational drugs for heart failure and a reduced ejection fraction	84
A Phase II study of autologous mesenchymal stromal cells and c‐kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN CONCERT‐HF	83
Ultrasound imaging of congestion in heart failure: examinations beyond the heart	83
Cost‐effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health‐economic analysis of DAPA‐HF	83
Temporal trends in decompensated heart failure and outcomes during COVID‐19: a multisite report from heart failure referral centres in London	82
Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure	81
Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA)	81
Unravelling the interplay between hyperkalaemia, renin–angiotensin–aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC‐HFA‐EORP Heart Failure Long	80
The prevalence and importance of frailty in heart failure with reduced ejection fraction – an analysis of PARADIGM‐HF and ATMOSPHERE	79
Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure	77
Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden)	76
Telemonitoring versus standard care in heart failure: a randomised multicentre trial	75
Association of COVID‐19 with impaired endothelial glycocalyx, vascular function and myocardial deformation 4 months after infection	75
Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta‐analysis	74
Impact of tricuspid regurgitation on survival in patients with heart failure: a large electronic health record patient‐level database analysis	74
Trial characteristics associated with under‐enrolment of females in randomized controlled trials of heart failure with reduced ejection fraction: a systematic review	72
Haemodynamic characteristics of COVID‐19 patients with acute respiratory distress syndrome requiring mechanical ventilation. An invasive assessment using right heart catheterization	71
Minimal clinically important difference in quality of life scores for patients with heart failure and reduced ejection fraction	70
Cachexia, muscle wasting, and frailty in cardiovascular disease	70
Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction	69
Regional adiposity and heart failure with preserved ejection fraction	68
Immunogenicity of the BNT162b2 mRNA vaccine in heart transplant recipients – a prospective cohort study	68
Trends in prevalence of comorbidities in heart failure clinical trials	67
Sodium–glucose co‐transporter 2 inhibitors as an early, first‐line therapy in patients with heart failure and reduced ejection fraction	67
Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of Cardiology (ESC	66
Characterization of NT‐proBNP in a large cohort of COVID‐19 patients	66
Unveiling outcomes in coexisting severe aortic stenosis and transthyretin cardiac amyloidosis	66
Heart Failure Association of the European Society of Cardiology update on sodium–glucose co‐transporter 2 inhibitors in heart failure	65
Temporal trends in mortality and readmission after acute heart failure: a systematic review and meta‐regression in the past four decades	65
Identification of distinct phenotypic clusters in heart failure with preserved ejection fraction	65
Obesity, venous capacitance, and venous compliance in heart failure with preserved ejection fraction	64
Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patients	63
Improving exercise capacity and quality of life using non‐invasive heart failure treatments: evidence from clinical trials	63
Heart failure management during the COVID‐19 outbreak in Italy: a telemedicine experience from a heart failure university tertiary referral centre	61
Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE‐MI): design and baseline characteristics	61
Caring for people with heart failure and many other medical problems through and beyond the COVID‐19 pandemic: the advantages of universal access to home telemonitoring	60
The cancer patient and cardiology	60
The impact of residual mitral regurgitation after MitraClip therapy in functional mitral regurgitation	59
Antigen carbohydrate 125 as a biomarker in heart failure: a narrative review	59
Sodium–glucose co‐transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial	58
Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subje	57

Ejection fraction and mortality: a nationwide register‐based cohort study of 499 153 women and men	57
Renal effects of guideline‐directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology	57
Interactions between left ventricular ejection fraction, sex and effect of neurohumoral modulators in heart failure	57
Digital health care solution for proactive heart failure management with the Cordella Heart Failure System: results of the SIRONA first‐in‐human study	56
Effect of dapagliflozin on anaemia in DAPA‐HF	56
Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy	55
Sex‐related differences in contemporary biomarkers for heart failure: a review	54
Myocarditis following COVID‐19 vaccine: incidence, presentation, diagnosis, pathophysiology, therapy, and outcomes put into perspective. A clinical consensus document supported by the Heart	53
Readmission and death in patients admitted with new‐onset versus worsening of chronic heart failure: insights from a nationwide cohort	52
The electrocardiogram in the diagnosis and management of patients with dilated cardiomyopathy	51
Contemporary survival trends and aetiological characterization in non‐ischaemic dilated cardiomyopathy	50
Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy	50
A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction – insights from the ESC‐HFA EORP Heart Failure Long‐Term Regist	48
In‐hospital care in acute heart failure during the COVID‐19 pandemic: insights from the German‐wide Helios hospital network	48
Italian Society of Interventional Cardiology (GIse) registry Of Transcatheter treatment of mitral valve regurgitaTiOn (GIOTTO): impact of valve disease aetiology and r	48
Acute coronary syndromes and acute heart failure: a diagnostic dilemma and high‐risk combination. A statement from the Acute Heart Failure Committee of the Heart Failure Association of the European So	48
Aspirin and left ventricular assist devices: rationale and design for the international randomized, placebo‐controlled, non‐inferiority ARIES HM3 trial	47
Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial	47
Decreases in acute heart failure hospitalizations during COVID‐19	47
OUTSTEP‐HF: randomised controlled trial comparing short‐term effects of sacubitril/valsartan versus enalapril on daily physical activity in patients with chronic heart failure with reduced ejection fr	46
Coronary microvascular dysfunction is associated with exertional haemodynamic abnormalities in patients with heart failure with preserved ejection fraction	46
Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta‐analysis of screening studies	46
One‐year results of the first‐in‐man study investigating the Atrial Flow Regulator for left atrial shunting in symptomatic heart failure patients: the PRELIEVE study	46
High soluble transferrin receptor in patients with heart failure: a measure of iron deficiency and a strong predictor of mortality	44
Virtual optimization of guideline‐directed medical therapy in hospitalized patients with heart failure with reduced ejection fraction: the IMPLEMENT‐HF pilot study	44
A prospective STudy using invAsive haemodynamic measurements foLLowing catheter ablation for AF and early HFpEF: STALL AF‐HFpEF	43
Congestion in heart failure: a circulating biomarker‐based perspective. A review from the Biomarkers Working Group of the Heart Failure Association, European Society of Cardiology	42
Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC‐HF baseline characteristics and comparison with contemporary clinical trials	42
The impact of palliative care on clinical and patient‐centred outcomes in patients with advanced heart failure: a systematic review of randomized controlled trials	41
Association between renin–angiotensin–aldosterone system inhibitor use and COVID‐19 hospitalization and death: a 1.4 million patient nationwide registry analysis	41
Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology	41
Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the AC‐TIVE study, an Italian nationwide survey	41
Phenotyping heart failure patients for iron deficiency and use of intravenous iron therapy: data from the Swedish Heart Failure Registry	40
Exercise testing in heart failure with preserved ejection fraction: an appraisal through diagnosis, pathophysiology and therapy – A clinical consensus statement of the Heart Failure Association and Eu	40
SARS‐CoV‐2‐related myocarditis‐like syndromes Shakespeare's question: what's in a name?	39
Recovery of cardiac function following COVID‐19 – ECHOVID‐19: a prospective longitudinal cohort study	39
Guideline‐directed medical therapy for heart failure does not exist: a non‐judgmental framework for describing the level of adherence to evidence‐based drug treatments for patients with a reduced ejec	39
Splanchnic nerve modulation in heart failure: mechanistic overview, initial clinical experience, and safety considerations	37
Long‐term clinical experience with cardiac contractility modulation therapy delivered by the Optimizer Smart system	37
Urinary peptides in heart failure: a link to molecular pathophysiology	37
Use of evidence‐based therapy in heart failure with reduced ejection fraction across age strata	36
Surgical ablation of the right greater splanchnic nerve for the treatment of heart failure with preserved ejection fraction: first‐in‐human clinical trial	36
Effects of exergaming on exercise capacity in patients with heart failure: results of an international multicentre randomized controlled trial	36
Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the Heart Failure Association of the Eu	36
Cardiac, renal, and metabolic effects of sodium–glucose co‐transporter 2 inhibitors: a position paper from the European Society of Cardiology ad‐hoc task force on sodium–glucose co‐transporter 2 inhib	36
Telemonitoring in patients with chronic heart failure and moderate depressed symptoms: results of the Telemedical Interventional Monitoring in Heart Failure (TIM‐HF) study	35
Worsening renal function in acute heart failure in the context of diuretic response	34
Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care	34
Transcatheter tricuspid valve repair in the setting of heart failure with preserved or reduced left ventricular ejection fraction	34
Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium–glucose co‐transporter 2 inhibitor therapy in DECLARE‐TIMI	34
Challenges and future perspectives of transcatheter tricuspid valve interventions: adopt old strategies or adapt to new opportunities?	34
Vericiguat in patients with atrial fibrillation and heart failure with reduced ejection fraction: insights from the VICTORIA trial	34
Transapical mitral valve implantation for treatment of symptomatic mitral valve disease: a real‐world multicentre experience	33
Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESC‐EORP Heart Failure Long‐Term Registry	33
The combination of carboxy‐terminal propeptide of procollagen type I blood levels and late gadolinium enhancement at cardiac magnetic resonance provides additional prognostic information in idiopathic	33
The HFA‐PEFF and H2FPEF scores largely disagree in classifying patients with suspected heart failure with preserved ejection fraction	33
Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA‐HF trial	33
Serum potassium in the PARADIGM‐HF trial	32
Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA‐HF	32
Cardiac iron concentration in relation to systemic iron status and disease severity in non‐ischaemic heart failure with reduced ejection fraction	32
Patiromer for the management of hyperkalaemia in patients receiving renin–angiotensin–aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial	32
Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index	32
Serum uric acid, influence of sacubitril–valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON‐HF	32
Impact of mitral regurgitation in patients with worsening heart failure: insights from BIOSTAT‐CHF	31
Characteristics and outcomes of patients screened for transcatheter mitral valve implantation: 1‐year results from the CHOICE‐MI registry	31
Pathophysiology of Takotsubo syndrome – a joint scientific statement from the Heart Failure Association Takotsubo Syndrome Study Group and Myocardial Function Working Group of the European Society of	31
Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR‐Reduced	31
Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology	31
Gut dysbiosis and heart failure: navigating the universe within	31
Use of biomarkers to diagnose and manage cardiac amyloidosis	31
MiRNA‐181a is a novel regulator of aldosterone–mineralocorticoid receptor‐mediated cardiac remodelling	31
Pathophysiology of Takotsubo syndrome – a joint scientific statement from the Heart Failure Association Takotsubo Syndrome Study Group and Myocardial Function Working Group of th	30
Targeting pulmonary capillary permeability to reduce lung congestion in heart failure: a randomized, controlled pilot trial	30
Natural history and impact of treatment with tafamidis on major cardiovascular outcome‐free survival time in a cohort of patients with transthyretin amyloidosis	30
Renal profiling based on estimated glomerular filtration rate and spot urine sodium identifies high‐risk acute heart failure patients	30
Pathogenesis and management of myocardial injury in coronavirus disease 2019	30
Epicardial fat in heart failure with reduced versus preserved ejection fraction	30
Use of sodium–glucose co‐transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry	30
Liver function and prognosis, and influence of sacubitril/valsartan in patients with heart failure with reduced ejection fraction	30
COVID‐19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology	30

A current and future outlook on upcoming technologies in remote monitoring of patients with heart failure	30
Association between dosing and combination use of medications and outcomes in heart failure with reduced ejection fraction: data from the Swedish Heart Failure Registry	30
The ergoreflex: how the skeletal muscle modulates ventilation and cardiovascular function in health and disease	29
Cardiac remodelling – Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology	29
Diabetes and pre‐diabetes in patients with heart failure and preserved ejection fraction	29
Concentration‐dependent clinical and prognostic importance of high‐sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin: the EMPEROR<	29
European Society of Cardiology quality indicators for the care and outcomes of adults with heart failure. Developed by the Working Group for Heart Failure Quality Indicators in collaboration with the	28
A network analysis to identify pathophysiological pathways distinguishing ischaemic from non‐ischaemic heart failure	28
Myocardial work and vascular dysfunction are partially improved at 12 months after COVID‐19 infection	28
Efficacy and safety of sodium–glucose co‐transporter 2 inhibition according to left ventricular ejection fraction in DAPA‐HF	28
Cardiac magnetic resonance in heart failure with preserved ejection fraction: myocyte, interstitium, microvascular, and metabolic abnormalities	28
Dietary interventions and nutritional supplements for heart failure: a systematic appraisal and evidence map	28
Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA‐HF	27
Natriuresis‐guided therapy in acute heart failure: rationale and design of the Pragmatic Urinary Sodium‐based treatment algoritHm in Acute Heart Failure (PUSH‐AHF) tri	27
Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre‐specified subgroup with heart fai	27
Intravenous iron in patients with heart failure and iron deficiency: an updated meta‐analysis	27
Incidence and risk factors for pacemaker implantation in light‐chain and transthyretin cardiac amyloidosis	27
Excess out‐of‐hospital deaths during the COVID‐19 outbreak: evidence of pulmonary embolism as a main determinant	27
Head‐to‐head comparison of contemporary heart failure risk scores	26
Natural history and prognostic significance of iron deficiency and anaemia in ambulatory patients with chronic heart failure	26
Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM‐AHF trial	26
Prognostic value of cardiopulmonary exercise testing in cardiac amyloidosis	26
The burden of non‐cardiac comorbidities and association with clinical outcomes in an acute heart failure trial – insights from ASCEND‐HF	26
Benefit of buspirone on chemoreflex and central apnoeas in heart failure: a randomized controlled crossover trial	26
Quality of life in men and women with heart failure: association with outcome, and comparison between the Kansas City Cardiomyopathy Questionnaire and the EuroQol 5 dimensions questionnaire	26
How can sodium–glucose cotransporter 2 inhibitors stimulate erythrocytosis in patients who are iron‐deficient? Implications for understanding iron homeostasis in heart failure	26
Practical outpatient management of worsening chronic heart failure	26
Effects of empagliflozin on erythropoiesis in heart failure: data from the Empire HF trial	25
Prevention of heart failure events with sodium–glucose co‐transporter 2 inhibitors across a spectrum of cardio‐renal‐metabolic risk	25
Proteomics to improve phenotyping in obese patients with heart failure with preserved ejection fraction	25
Early risk stratification in patients with cardiogenic shock irrespective of the underlying cause – the Cardiogenic Shock Score	25
Frequency, trends and institutional variation in 30‐day all‐cause mortality and unplanned readmissions following hospitalisation for heart failure in Australia and New Zealand	25
Eligibility for mechanical circulatory support devices based on current and past randomised cardiogenic shock trials	25
Endovascular ablation of the right greater splanchnic nerve in heart failure with preserved ejection fraction: early results of the REBALANCE‐HF trial roll‐in cohort	25
Transfer of a human gene variant associated with exceptional longevity improves cardiac function in obese type 2 diabetic mice through induction of the SDF‐1/CXCR4 signalling pat	25
Effects of hyperkalaemia and non‐adherence to renin–angiotensin–aldosterone system inhibitor therapy in patients with heart failure in Italy: a propensity‐matched study	25
In‐hospital initiation of quadruple medical therapy for heart failure: making the post‐discharge vulnerable phase far less vulnerable	25
Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR‐Preserved trial	25
Diagnostic scores predict morbidity and mortality in patients hospitalized for heart failure with preserved ejection fraction	24
Intravenous immunoglobulin therapy in adult patients with idiopathic chronic cardiomyopathy and cardiac parvovirus B19 persistence: a prospective, double‐blind, randomized, placebo‐controll	24
Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis	24
Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta‐analysis	24
Spironolactone dose in heart failure with preserved ejection fraction: findings from TOPCAT	24
Evaluation of high‐sensitivity C‐reactive protein and uric acid in vericiguat‐treated patients with heart failure with reduced ejection fraction	24
National trends in heart failure mortality in men and women, United Kingdom, 2000–2017	24
The significance of left ventricular ejection time in heart failure with reduced ejection fraction	24
Epicardial adipose tissue related to left atrial and ventricular function in heart failure with preserved versus reduced and mildly reduced ejection fraction	24
Prevalence, characteristics and outcomes of older patients with hereditary versus wild‐type transthyretin amyloid cardiomyopathy	24
Effects of combined renin–angiotensin–aldosterone system inhibitor and beta‐blocker treatment on outcomes in heart failure with reduced ejection fraction: insights from BIOSTAT‐CHF and	24
Long‐term survival and life expectancy following an acute heart failure hospitalization in Australia and New Zealand	23
Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA‐REG OUTCOME trial	23
Incorporation of natriuretic peptides with clinical risk scores to predict heart failure among individuals with dysglycaemia	23
Value of the HFA‐PEFF and H2FPEF scores in patients with heart failure and preserved ejection fraction caused by cardiac amyloidosis	23
Integration of imaging and circulating biomarkers in heart failure: a consensus document by the Biomarkers and Imaging Study Groups of the Heart Failure Association of the European Society of Cardiolo	23
Increased resting heart rate and prognosis in treatment‐naïve unselected cancer patients: results from a prospective observational study	23
Systemic embolism in amyloid transthyretin cardiomyopathy	23
Central haemodynamic abnormalities and outcome in patients with unexplained dyspnoea	23
Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO‐DKD trial	22
Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA‐HF	22
The Heart Failure Association Atlas: rationale, objectives, and methods	22
Standardized definitions for evaluation of heart failure therapies: scientific expert panel from the Heart Failure Collaboratory and Academic Research Consortium	22
Effect of patient‐centered transitional care services on patient‐reported outcomes in heart failure: sex‐specific analysis of the PACT‐HF randomized controlled trial	22
Heart Failure Association of the European Society of Cardiology Quality of Care Centres Programme: design and accreditation document	22
Uncoupling between intravascular and distending pressures leads to underestimation of circulatory congestion in obesity	22
Prognostic impact of the updated 2018 HFA‐ESC definition of advanced heart failure: results from the HELP‐HF registry	22
Use of guideline‐recommended medical therapy in patients with heart failure and chronic kidney disease: from physician's prescriptions to patient's dispensations, medication adherence and persistence	22
Sex and central obesity in heart failure with preserved ejection fraction	21
Clonal haematopoiesis is associated with higher mortality in patients with cardiogenic shock	21
Baroreflex activation therapy with the Barostim™ device in patients with heart failure with reduced ejection fraction: a patient level meta‐analysis of randomized controlled trials	21
Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the EMPULSE trial	21
Effects of an outpatient intervention comprising nurse‐led non‐invasive assessments, telemedicine support and remote cardiologists' decisions in patients with heart failure (AMULET study):	21
Prognostic impacts of dynamic cardiac structural changes in heart failure patients with preserved left ventricular ejection fraction	21
Biomarker‐driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR–Preserved trial	21
Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR‐Preserved trial	21
Impact of left atrial diameter on outcome in patients undergoing edge‐to‐edge mitral valve repair: results from the German TRAnscatheter Mitral valve Interventions (TRAMI) regist	21
Sex differences among patients with transthyretin amyloid cardiomyopathy – from diagnosis to prognosis	21
Ventricular tachyarrhythmia detection by implantable loop recording in patients with heart failure and preserved ejection fraction: the VIP‐HF study	21
Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Gro	21
Relationship between left ventricular ejection fraction and cardiovascular outcomes following hospitalization for heart failure: insights from the RELAX‐AHF‐2 trial	21
The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study	21
Genetic and phenotypic profiling of supranormal ejection fraction reveals decreased survival and underdiagnosed heart failure	21
Pharmacotherapy for heart failure with reduced ejection fraction and health‐related quality of life: a systematic review and meta‐analysis	21
Cardiac remodelling – Part 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology	21
Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm A	20
Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM‐HF trial	20
Heart failure treatment up‐titration and outcome and age: an analysis of BIOSTAT‐CHF	20
Viral presence‐guided immunomodulation in lymphocytic myocarditis: an update	20
Acceleration of kidney function decline after incident hospitalization with cardiovascular disease: the Stockholm CREAtinine Measurements (SCREAM) project	20
Navigating between Scylla and Charybdis: challenges and strategies for implementing guideline‐directed medical therapy in heart failure with reduced ejection fraction	20
A randomized clinical trial on the short‐term effects of 12‐week sacubitril/valsartan vs. enalapril on peak oxygen consumption in patients with heart failure with reduced ejection fraction: results fr	20
Ferric carboxymaltose for the treatment of iron deficiency in heart failure: a multinational cost‐effectiveness analysis utilising AFFIRM‐AHF	20
A machine learning risk score predicts mortality across the spectrum of left ventricular ejection fraction	20
Heart failure with preserved ejection fraction according to the HFA‐PEFF score in COVID‐19 patients: clinical correlates and echocardiographic findings	20
Left atrial disease and left atrial reverse remodelling across different stages of heart failure development and progression: a new target for prevention and treatment	20
Cardiac output states in patients with severe functional tricuspid regurgitation: impact on treatment success and prognosis	19